CMS NEWS
FOR IMMEDIATE RELEASE
March 13, 2020
Contact: CMS Media
Relations
(202) 690-6145 | CMS Media Inquiries
CMS Publishes FAQs to Ensure Individuals, Issuers and States
have Clear Information on Coverage Benefits for COVID-19
Information details existing federal rules governing health
coverage that apply to diagnosis and treatment of COVID-19
Today, the Centers for
Medicare & Medicaid Services (CMS) is posting Frequently Asked Questions
(FAQs) on Essential Health Benefits (EHB) Coverage in response to the 2019
Novel Coronavirus (COVID-19) outbreak. This action is part of the
broader, ongoing effort by the White House Coronavirus Task Force to ensure
that all Americans – particularly those at high-risk of complications from
the COVID-19 virus – have access to the health benefits that can help keep
them healthy while helping to contain the spread of this disease.
“Amid a serious outbreak
like this one, Americans understandably crave the security and peace of mind
that comes from understanding exactly how they will be covered.” said CMS
Administrator Seema Verma. “Today’s guidance aims to give it to them. Working
closely with states and issuers around the country, the Trump Administration
will continue to provide pertinent information to strengthen the nation’s
response and keep Americans informed.”
The FAQs released today
detail existing federal rules governing health coverage provided through the
individual and small group insurance markets that apply to the diagnosis and
treatment of COVID-19. The FAQs clarify which COVID-related services,
including testing, isolation/quarantine, and vaccination, are generally
currently covered as EHBs in these markets. The purpose of the FAQs is
to provide guidance to Americans enrolled in individual or small group market
health plans, including HealthCare.gov consumers. As questions and issues
continue to come to CMS, they will be addressed and added to these FAQs.
Earlier this week,
President Trump and Vice President Pence held a meeting with leading
insurance companies and their industry associations in which many health
insurance issuers announced they will be treating COVID-19 diagnostic tests
as covered benefits and will be waiving cost-sharing that would otherwise
apply to the tests. States are the primary regulators of health coverage and
are continuing to work with issuers to ensure coverage of COVID-19 related
services. Patients should contact their insurer to determine specific
benefits and coverage policies, as these details may vary by state and by
plan.
The COVID-19 FAQs for EHB
can be found here: https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/Downloads/EHB-Benchmark-Coverage-of-COVID-19.pdf
These FAQs, and earlier
CMS actions in response to the COVID-19 virus, are part of the ongoing White
House Task Force efforts. To keep up with the important work the Task Force
is doing in response to COVID-19 click here www.coronavirus.gov. For information
specific to CMS, please visit the Current Emergencies Website.
Summary of CMS Public
Health Action on COVID-19 to date:
March 12, 2020: CMS issued
Frequently Asked Questions (FAQs) to aid state Medicaid and Children’s Health
Insurance Program (CHIP) agencies in their response to the 2019 Novel
Coronavirus (COVID-19) outbreak. CMS is taking this action in its continuing
efforts to protect the health and safety of providers and patients, including
those who are covered by Medicaid and CHIP.
March 10, 2020: CMS issued
guidance to home health agencies and dialysis facilities with actionable
information for healthcare workers on screening, treatment and transfer
procedures to follow when interacting with patients in response to the 2019
Novel Coronavirus (COVID-19) outbreak.
March 10, 2020: CMS issued
a frequently asked questions to ensure State Survey Agencies and
accrediting organizations charged with inspecting nursing homes and other
health care facilities, understand that non-emergency survey inspections are
suspended. This shift in survey prioritization enables State Inspectors to
address the spread of the 2019 Novel Coronavirus Disease (COVID-19).
March 10, 2020: CMS issued
guidance on Medicare Advantage (MA) and Part D health and prescription drug
plans informing them of the flexibilities they have to provide healthcare
coverage for testing, treatments, and prevention of 2019 Novel Coronavirus Disease
(COVID-19). Leading insurance companies and their industry associations
announced they will be treating COVID-19 diagnostic tests as covered benefits
and will be waiving cost sharing that would otherwise apply to the test.
March 10, 2020:
CMS issued guidance on the range of facemasks that can be temporarily
used based on recent changes to CDC and FDA facemask and respirator guidance
in light of COVID-19 and supply demands. These are steps the White House Task
Force is taking to ensure a maximum supply of facemasks and respirators are
available that allow healthcare providers to safely treat patients without
exposing themselves or others to COVID-19.
On March 9, 2020: CMS
delivered detailed guidance on the screening, treatment and transfer
procedures healthcare workers must follow when interacting with patients to
prevent the spread of COVID-19 in a hospice setting. CMS also issued
additional guidance specific to nursing homes to help control and prevent the
spread of the virus.
On March 9, 2020: CMS
issued a fact sheet with additional guidance for healthcare providers and
patients about the telehealth benefits in the agency’s Medicare
program. Expanded use of virtual care, such as virtual check-ins, are
important tools for keeping beneficiaries healthy, while helping to contain
the community spread of the COVID-19 virus.
On March 9, 2020:
CMS published guidance to hospitals with emergency departments (EDs) on
patient screening, treatment and transfer requirements to prevent the
spread of infectious disease and illness, including
COVID-19. Medicare-participating hospitals are to follow both CDC
guidance for infection control and Emergency Medical Treatment and Labor Act
(EMTALA) requirements.
March 6, 2020: CMS issued
frequently asked questions and answers (FAQs) for healthcare providers
regarding Medicare payment for laboratory test and other services related to
the 2019-Novel Coronavirus (COVID-19).
March 5, 2020: CMS issued
a second Healthcare Common Procedure Coding System (HCPCS) code for certain
COVID-19 laboratory tests, in addition to three fact sheets about coverage
and benefits for medical services related to COVID-19 for CMS programs.
March 4, 2020: CMS issued
a call to action to healthcare providers nationwide and offered important
guidance to help State Survey Agencies and Accrediting Organizations
prioritize their inspections of healthcare.
February 13, 2020: CMS
issued a new HCPCS code for providers and laboratories to test patients for
COVID-19.
February 6, 2020: CMS gave
CLIA-certified laboratories information about how they can test for
SARS-CoV-2.
February 6, 2020: CMS
issued a memo to help the nation’s healthcare facilities take critical steps
to prepare for COVID-19.
###
Get CMS news at cms.gov/newsroom, sign up for CMS news via email and follow CMS on Twitter CMS
Administrator @SeemaCMS, @CMSgov, and @CMSgovPress.
|
|
|
To be a Medicare Agent's source of information on topics affecting the agent and their business, and most importantly, their clientele, is the intention of this site. Sourced from various means rooted in the health insurance industry - insurance carriers, governmental agencies, and industry news agencies, this is aimed as a resource of varying viewpoints to spark critical thought and discussion. We welcome your contributions.
Friday, March 13, 2020
CMS Publishes FAQs to Ensure Individuals, Issuers and States have Clear Information on Coverage Benefits for COVID-19
Subscribe to:
Post Comments (Atom)


No comments:
Post a Comment